Literature DB >> 23704039

Successful bypass restenting across the struts of an occluded subintimal stent in chronic total occlusion using a retrograde approach.

Hidefumi Ohya1, Eisho Kyo, Osamu Katoh.   

Abstract

Recently, subintimal angioplasty has been introduced as a bailout strategy to improve the success rate of PCI for vessels with CTO. However, the long-term outcome of subintimal angioplasty has not been determined, and a limitation of subintimal angioplasty is the uncertainty in making the re-entry point. We report two cases, where occlusive in-stent restenosis occurred in a stent implanted in the subintimal space of the RCA that had CTO. These two cases were successfully treated with bypass restenting across the struts of an occluded subintimal stent using a retrograde approach. A retrograde wire crossed the occluded segment through the lumen along the outside of the stent and reentered the inside of the stent across the stent struts. The reverse CART technique followed by multiple restenting across the stent struts restored antegrade flow. Follow-up angiography demonstrated the patency of the RCA.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  bypass restenting; occlusive ISR; percutaneous coronary intervention; retrograde approach; subintimal angioplasty; total occlusions

Mesh:

Year:  2013        PMID: 23704039     DOI: 10.1002/ccd.25012

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  1 in total

1.  The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry.

Authors:  Georgios Christopoulos; Dimitri Karmpaliotis; Khaldoon Alaswad; William L Lombardi; J Aaron Grantham; Bavana V Rangan; Anna P Kotsia; Nicholas Lembo; David E Kandzari; James Lee; Anna Kalynych; Harold Carlson; Santiago Garcia; Subhash Banerjee; Craig A Thompson; Emmanouil S Brilakis
Journal:  Catheter Cardiovasc Interv       Date:  2014-07-04       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.